[go: up one dir, main page]

AR063153A1 - Anticuerpo monoclonal para prevenir/tratar el cancer - Google Patents

Anticuerpo monoclonal para prevenir/tratar el cancer

Info

Publication number
AR063153A1
AR063153A1 ARP070104425A ARP070104425A AR063153A1 AR 063153 A1 AR063153 A1 AR 063153A1 AR P070104425 A ARP070104425 A AR P070104425A AR P070104425 A ARP070104425 A AR P070104425A AR 063153 A1 AR063153 A1 AR 063153A1
Authority
AR
Argentina
Prior art keywords
nectin
prevent
monoclonal antibody
treat cancer
cancer
Prior art date
Application number
ARP070104425A
Other languages
English (en)
Inventor
Sato Shuji
Oshima Tsutomu
Kurokawa Tomofumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44083820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063153(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2006/320429 external-priority patent/WO2007043635A1/ja
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR063153A1 publication Critical patent/AR063153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo monoclonal humano contra una proteína que comprende la misma o sustancialmente la misma secuencia de aminoácidos que la secuencia de aminoácidos representada por la SEC ID N°:1 o SEC ID N°: 3, su péptido parcial o una sal del mismo, es util como agente para prevenir/tratar el cáncer. Un inductor de apoptosis de células cancerosas, un inhibidor del crecimiento de células cancerosas, un agente citotoxico contra células cancerosas a través de un mecanismo de defensa del huésped mediado por la region FC de un anticuerpo y demás. Reivindicacion 9: El anticuerpo de acuerdo con la reivindicacion 1, caracterizado porque tiene actividad inhibitoria de la union trans de nectina-2/nectina-3 o nectina-2/nectina-2. Reivindicacion 15: Una célula de hibridoma, caracterizado porque es capaz de producir el anticuerpo de acuerdo con la reivindicacion 1.
ARP070104425A 2006-10-06 2007-10-09 Anticuerpo monoclonal para prevenir/tratar el cancer AR063153A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2006/320429 WO2007043635A1 (ja) 2005-10-07 2006-10-06 癌の予防・治療剤
CL200700974A CL2007000974A1 (es) 2005-10-07 2007-04-05 Anticuerpo monoclonal anti-nectina 2; composicion farmaceutica que lo comprende; y su uso para tratar o prevenir el cancer.
JP2007100876 2007-04-06

Publications (1)

Publication Number Publication Date
AR063153A1 true AR063153A1 (es) 2008-12-30

Family

ID=44083820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104425A AR063153A1 (es) 2006-10-06 2007-10-09 Anticuerpo monoclonal para prevenir/tratar el cancer

Country Status (21)

Country Link
US (1) US20100008928A1 (es)
EP (1) EP2067791A4 (es)
JP (1) JPWO2008044754A1 (es)
KR (1) KR20090078339A (es)
CN (1) CN101541834A (es)
AR (1) AR063153A1 (es)
AU (1) AU2007307536A1 (es)
BR (1) BRPI0717024A2 (es)
CA (1) CA2666249A1 (es)
CL (1) CL2007002879A1 (es)
CO (1) CO6190538A2 (es)
EC (1) ECSP099276A (es)
IL (1) IL197389A0 (es)
MA (1) MA30816B1 (es)
MX (1) MX2009003126A (es)
NO (1) NO20091783L (es)
PE (1) PE20081456A1 (es)
RU (1) RU2009117237A (es)
TN (1) TN2009000090A1 (es)
TW (1) TW200823235A (es)
WO (1) WO2008044754A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683054B2 (en) * 2010-12-31 2017-06-20 BioAlta, LLC Express humanization of antibodies
CA2844040C (en) * 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2858673A4 (en) * 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
WO2014069681A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2014069682A1 (ko) * 2012-10-29 2014-05-08 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
CN110799213A (zh) 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
US11214619B2 (en) 2018-07-20 2022-01-04 Surface Oncology, Inc. Anti-CD112R compositions and methods
CA3125962A1 (en) * 2019-01-13 2020-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin-2
CN113527486B (zh) * 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
AU2022208054A1 (en) 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
WO2022170002A1 (en) 2021-02-03 2022-08-11 Seagen Inc. Immunostimulatory compounds and conjugates
IL314622A (en) * 2022-02-28 2024-09-01 Nectin Therapeutics Ltd Humanized antibodies against Nectin-2 and their drug conjugates
US20250255981A1 (en) 2022-05-06 2025-08-14 Seagen Inc. Immunomodulatory antibody-drug conjugates
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1999063063A1 (en) 1998-06-03 1999-12-09 Northwestern University Cellular proteins which mediate herpesvirus entry
US20030129685A1 (en) * 1998-10-28 2003-07-10 Jian Ni 12 human secreted proteins
DE19852800C1 (de) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Verfahren zur Herstellung von Antikörpern gegen ein Polypeptid, von dem die kodierende Nukleinsäure bekannt ist
US20030022279A1 (en) * 1999-06-14 2003-01-30 Fraser Christopher C. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
MXPA03002479A (es) 2000-10-05 2004-05-24 Immunex Corp Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
EP1572872A2 (en) 2001-06-05 2005-09-14 Exelixis, Inc. Igs as modifiers of the p53 pathway and methods of use
CA2449303C (en) 2001-06-06 2014-10-14 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030084468A1 (en) 2001-09-05 2003-05-01 Economides Aris N. Methods of expressing transgenes
AU2003230874A1 (en) * 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2500687A1 (en) 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2070546A1 (en) * 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer

Also Published As

Publication number Publication date
KR20090078339A (ko) 2009-07-17
CN101541834A (zh) 2009-09-23
AU2007307536A1 (en) 2008-04-17
NO20091783L (no) 2009-07-01
PE20081456A1 (es) 2008-11-27
US20100008928A1 (en) 2010-01-14
TW200823235A (en) 2008-06-01
WO2008044754A1 (en) 2008-04-17
CL2007002879A1 (es) 2008-06-27
BRPI0717024A2 (pt) 2014-03-11
MA30816B1 (fr) 2009-10-01
AU2007307536A2 (en) 2009-04-30
JPWO2008044754A1 (ja) 2010-02-18
RU2009117237A (ru) 2010-11-20
CO6190538A2 (es) 2010-08-19
MX2009003126A (es) 2009-04-06
TN2009000090A1 (en) 2010-08-19
EP2067791A4 (en) 2009-11-25
CA2666249A1 (en) 2008-04-17
IL197389A0 (en) 2011-08-01
ECSP099276A (es) 2009-06-30
EP2067791A1 (en) 2009-06-10

Similar Documents

Publication Publication Date Title
AR063153A1 (es) Anticuerpo monoclonal para prevenir/tratar el cancer
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
AR065289A1 (es) Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
PH12014501083A1 (en) Anticancer fusion protein
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
NZ812025A (en) Polypeptide variants and uses thereof
AR066338A1 (es) Proteinas toxinas activas contra hemipteros y coleopteros de bacillus thuringiensis
GEP20115324B (en) Tweak binding antibodies
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
PE20110310A1 (es) Axmi-115, axmi-113, axmi-005, axmi-163 y axmi-184: proteinas insecticidas
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
EA201390820A1 (ru) Слитый белок против рака
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
EA201391546A1 (ru) Противораковый слитый белок
AR060362A1 (es) Agente para prevenir / tratar el cancer
NZ583429A (en) Peptides and proteins capable of inhibiting and/or preventing mast cell activation
MX376386B (es) Composiciones para usarse en el tratamiento de patologías del tejido de cartílago y disco.
PH12014502198B1 (en) Osteoprotegerin derived composition and use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure